Optimal Omeprazole Dosing and Symptom Control: A Randomized Controlled Trial (OSCAR Trial)

[1]  D. Graham,et al.  Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  Karl Broich,et al.  Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. , 2016, JAMA neurology.

[3]  Josef Coresh,et al.  Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. , 2016, JAMA internal medicine.

[4]  M. Wolfe,et al.  Consumer Use of Over-the-Counter Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease , 2014, The American Journal of Gastroenterology.

[5]  M. Vaezi,et al.  High Economic Burden of Caring for Patients With Suspected Extraesophageal Reflux , 2013, The American Journal of Gastroenterology.

[6]  N. Abraham.  Proton pump inhibitors: potential adverse effects , 2012, Current opinion in gastroenterology.

[7]  D. Johnson,et al.  Burden of Gastro-Oesophageal Reflux Disease in Patients with Persistent and Intense Symptoms Despite Proton Pump Inhibitor Therapy , 2011, Clinical drug investigation.

[8]  P. Moayyedi,et al.  WITHDRAWN: Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. , 2010, The Cochrane database of systematic reviews.

[9]  M. McDonagh,et al.  Drug Class Review: Proton Pump Inhibitors: Final Report Update 5 , 2009 .

[10]  J. Everhart,et al.  Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. , 2009, Gastroenterology.

[11]  A. Zinsmeister,et al.  Overlap of gastro‐oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population , 2007, Alimentary pharmacology & therapeutics.

[12]  D. Metz,et al.  On-Demand Therapy for Gastroesophageal Reflux Disease , 2007, The American Journal of Gastroenterology.

[13]  P. Wahlqvist,et al.  Systematic review: the impact of gastro‐oesophageal reflux disease on work productivity , 2006, Alimentary pharmacology & therapeutics.

[14]  R. Fass,et al.  Systematic review: proton‐pump inhibitor failure in gastro‐oesophageal reflux disease – where next? , 2005, Alimentary pharmacology & therapeutics.

[15]  G. Sachs,et al.  Inhibitor and ion binding sites on the gastric H,K-ATPase. , 2005, Biochemistry.

[16]  D. Graham,et al.  Gastroesophageal reflux among different racial groups in the United States. , 2004, Gastroenterology.

[17]  T. Ferris,et al.  Who is Using Chronic Acid Suppression Therapy and Why? , 2003, American Journal of Gastroenterology.

[18]  Clifford Goodman,et al.  The burden of selected digestive diseases in the United States. , 2002, Gastroenterology.

[19]  G. Sachs,et al.  Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. , 2000, Gastroenterology.

[20]  K. Rodvold.  Clinical Pharmacokinetics of Clarithromycin , 1999, Clinical pharmacokinetics.

[21]  A. Hungin,et al.  Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. , 1999, The British journal of general practice : the journal of the Royal College of General Practitioners.

[22]  J. Galmiche,et al.  Treating the symptoms of gastro‐oesophageal reflux disease: a double‐blind comparison of omeprazole and cisapride , 1997, Alimentary pharmacology & therapeutics.

[23]  R. Hunt,et al.  Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. , 1997, Gastroenterology.

[24]  A R Zinsmeister,et al.  Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. , 1997, Gastroenterology.

[25]  A. Pilotto,et al.  A comparison of five maintenance therapies for reflux esophagitis. , 1995, The New England journal of medicine.

[26]  C D Schleck,et al.  Dyspepsia and dyspepsia subgroups: a population-based study. , 1992, Gastroenterology.

[27]  E. C. Wood,et al.  Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. , 1984, Gut.

[28]  S. Passaretti,et al.  Ranitidine vs metoclopramide in the medical treatment of reflux esophagitis. , 1983, Hepato-gastroenterology.

[29]  G. Sachs,et al.  Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+) ATPase , 1981, Nature.

[30]  G. Sachs,et al.  A nonelectrogenic H+ pump in plasma membranes of hog stomach. , 1976, The Journal of biological chemistry.

[31]  S. Jenkins,et al.  Sclerosing encapsulating peritonitis: a case series from a single U.K. center during a 10-year period. , 2001, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.